Resolution Therapeutics presents hopeful data on regenerative macrophage therapy for cirrhosis at AASLD 2025 Resolution Therapeutics has announced new data from its portfolio of macrophage-based therapies at the AASLD 2025 conference. The company highlighted early clinical signals from the MATCH Phase II study, which evaluate the potential of non-engineered macrophages to repair cirrhotic livers and…